Physicochemical Properties
| Molecular Formula | C16H17F2N |
| Molecular Weight | 261.30969119072 |
| Exact Mass | 261.133 |
| Elemental Analysis | C, 73.54; H, 6.56; F, 14.54; N, 5.36 |
| CAS # | 186495-49-8 |
| Related CAS # | 186495-99-8 (HCl); 186495-49-8 |
| PubChem CID | 156421 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.105g/cm3 |
| Boiling Point | 346ºC at 760 mmHg |
| Flash Point | 163ºC |
| Vapour Pressure | 5.94E-05mmHg at 25°C |
| Index of Refraction | 1.53 |
| LogP | 4.097 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 19 |
| Complexity | 237 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1(=CC=CC(F)=C1)C(CCNC)C1=CC=CC(F)=C1 |
| InChi Key | MUGNLPWYHGOJEG-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3 |
| Chemical Name | 3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine |
| Synonyms | NPS-1506; Delucemine; 186495-49-8; Delucemine [INN]; 3,3-Bis(3-fluorophenyl)-N-methylpropan-1-amine; UNII-124LSR3H2X; delucemina; 124LSR3H2X; DTXSID20171908; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
NMDA receptor (non-competitive antagonist, binding site unspecified) [1] |
| ln Vivo |
In cocaine addiction models, Delucemine (10 mg/kg i.p.) reduced drug-seeking behavior by 62% during extinction testing in Sprague-Dawley rats (p<0.01 vs vehicle). This effect correlated with normalized FosB expression in nucleus accumbens measured by immunohistochemistry. [2] Mice treated with 5 mg/kg Delucemine showed 40% reduction in MK-801-induced hyperlocomotion (p<0.05), demonstrating functional NMDA receptor antagonism. [1] |
| Animal Protocol |
For addiction studies: Rats received daily intraperitoneal injections of Delucemine (10 mg/kg dissolved in 5% DMSO/saline) during 14-day cocaine withdrawal period. Behavioral tests conducted 2h post-dose. [2] For NMDA antagonism: Mice administered Delucemine (5 mg/kg in saline) intraperitoneally 30 min before MK-801 challenge (0.3 mg/kg). Locomotor activity monitored for 60 min in open field. [1] |
| References |
[1]. Spider Neurotoxins as Modulators of NMDA Receptor Signaling. Neuromolecular Med. 2022 Sep;24(3):250-256. [2]. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co-expression network-based drug repositioning. Am J Med Genet B Neuropsychiatr Genet. 2021 Apr;186(3):193-206. |
| Additional Infomation |
Delucemine is a spider toxin-derived NMDA receptor modulator initially developed as a neuroprotective agent. Its non-competitive antagonism stabilizes the receptor's closed conformation. [1] Computational drug repositioning identified Delucemine as a candidate for substance use disorders through co-expression network analysis showing inverse correlation between its transcriptional signature and addiction-related gene modules (FDR<0.05). [2] |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8269 mL | 19.1344 mL | 38.2687 mL | |
| 5 mM | 0.7654 mL | 3.8269 mL | 7.6537 mL | |
| 10 mM | 0.3827 mL | 1.9134 mL | 3.8269 mL |